Hepatitis C Drugs Market 2019 | Rapid Growth by Key Players Merck & Co. Inc., Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb

According to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C.

Increasing prevalence of hepatitis C will drive growth of hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will further propel growth of hepatitis C drug market.

Request Sample Copy of Industry Experts: https://www.coherentmarketinsights.com/insight/request-sample/1489 

The governmental initiatives for patients to receive expanded drug coverage is also expected to drive growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.

There are significant number of drugs available for Hepatitis C over the past few years and is expected to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment.

The pipeline consists of dual as well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more effective for the treatment of hepatitis C as compared to single regimen. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6.

Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid patients.

PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1489

The major players in hepatitis C drug market include Merck & Co. Inc., Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.